Leaders in DNA Damage Repair Biology

  • At the forefront of emerging cancer biology and genome-scale synthetic lethal screening approaches
  • World-class SAB and advisors
  • Global KOL collaborator network
MEET THE TEAM

Validated Discovery
Platform

  • Genome-wide CRISPR/Cas9 Synthetic Lethal screening technology
  • Structure-based Drug Design (SBDD)
  • Crystallography and structural biology
  • Bioinformatics and computational biology
LEARN ABOUT PLATFORM

First-in-Class Assets & Promising New Targets

  • Lead PolQ program with exciting mono- and combination-therapy potential across major indications
  • Additional programs addressing targets synthetic lethal with multiple important pathways
  • New pathways, targets and mechanistic insights emerging from novel synthetic lethal networks
EXPLORE PIPELINE

Repare Therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare’s platform combines a proprietary, high throughput, CRISPR‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics.